Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
Launched by PEKING UNIVERSITY THIRD HOSPITAL ·
Trial Information
Current as of September 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new ultrasound technique called super-resolution ultrasound (SRUS) to see if it can better tell the difference between harmless (benign) and harmful (malignant) swollen lymph nodes. Lymph nodes are small glands that help your body fight infections, but sometimes they can become enlarged due to different reasons like infections, cancer, or other diseases. Regular ultrasound scans can help doctors look at these lymph nodes, but they sometimes can’t clearly show the tiny blood vessels inside, which are important for understanding what’s causing the swelling. SRUS is a newer method that can create clearer images of these small blood vessels, potentially helping doctors make a more accurate diagnosis.
People aged 65 and older who have enlarged lymph nodes may be eligible to join this study. If you take part, you will have an ultrasound scan using this special SRUS technique to examine your lymph nodes more closely. The study will compare blood flow patterns in benign versus malignant lymph nodes to see how well SRUS can distinguish between them. This research could lead to better ways to diagnose lymph node problems without needing more invasive tests. The trial is currently recruiting participants and welcomes people of all genders.
Gender
ALL
Eligibility criteria
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
li g cui, Chief Physician
Study Chair
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported